31
Joanne J Bronson, Stanley V D Andrea, Shelley E Hoeft, John D Matiskella, Peter F Misco Jr, Bing Yu Luh, Dane M Springer, Yasutsugu Ueda, John A Wichtowski: Substituted 4-thio pyridones. Bristol Myers Squibb Company, David M Morse, September 16, 1997: US05668290

Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl or pyridyl group; R.sup.1 represents either the residue of a heterocyclic amino acid or a C.sub.2 - ...


32
Richard A Hartz, Vijay T Ahuja, Vivekananda M Vrudhula, Joanne J Bronson: )-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity, (. Bristol Myers Squibb Company, James Epperson, April 26, 2011: US07932256

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neu ...


33
Richard A Hartz, Vijay T Ahuja, Vivekananda M Vrudhula, Joanne J Bronson: Pyrazinone modulator of corticotropin-releasing factor receptor activity. Bristol Myers Squibb Company, James Epperson, February 12, 2013: US08372847

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neu ...


34

35
Joanne J Bronson, Katharine M Greene, Anita Lewin: Alicyclic phospholipase a2 inhibitors. Bristol Myers Squibb Company, HUANG GESHENG, March 1, 1995: CN94106460

Certain novel alicyclic compounds are effective phospholipase A2 (PLA2) inhibitors.


36

37
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors. Stephen B Davis, Bristol Myers Squibb Company, July 1, 2004: US20040127494-A1

There is provided a series of novel -(N-sulfonamido)acetamide compounds of the Formula (I) 1 wherein R, R1, R2 and R3 are defined herein, which are inhibitors of -amyloid peptide (-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid act ...


38
B Narasimhulu Naidu, Wenying Li, Kin S Lam, Margaret E Sorenson, John A Wichtowski, Timothy P Connolly, Yasutsugu Ueda, Joanne J Bronson, Yunhui Zhang, Oak K Kim: Water soluble thiazolyl peptide derivatives. Marla J Mathias, Bristol Myers Squibb Company, May 30, 2002: US20020065219-A1

Novel thiazolyl peptide compounds useful for the treatment of serious bacterial infections, and pharmaceutical compositions thereof are provided. More particularly, novel thiazolyl peptide compounds are provided having the general formula I: 1 wherein Q, Y and R areas defined in the specification.


39
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: Alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors. Bristol Myers Squibb Company, Louis J Wille, Bristol Myers Squibb Company, April 10, 2008: US20080085894-A1

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


40
Michael F Parker, Joanne J Bronson, Mark V Silva, Kevin W Gillman: Substituted heterocyclic ethers and their use in cns disorders. Bristol Myers Squibb Company, Louis J Wille, Bristol Myers Squibb Company, January 31, 2008: US20080027056-A1

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.